ALLMedicine™ Angina Pectoris Center

Mar 18th, 2023 - Coronary heart disease combined with depression is 1 of the 2 major diseases affecting physical and mental health. It has become a hot spot at the intersection of psychiatry and internal medicine. Most doctors call double heart medicine, which has...

Mar 14th, 2023 - Uric acid (UA) to albumin ratio (UAR) is an emerging marker to predict coronary artery disease (CAD)-related events. There is limited data on the relationship between UAR and the severity of the disease in chronic CAD patients. We aimed to evaluat...

Mar 11th, 2023 - The global prevalence of type 2 diabetes mellitus (T2DM) is growing yearly. The efficacy of ertugliflozin (ERT), a recently licensed anti-diabetic drug, has been widely reported. However, additional evidence-based data is required to ensure its sa...

Mar 11th, 2023 - Treatment with phosphodiesterase type 5 inhibitors (PDE-5is) is effective in treating erectile dysfunction (ED). The objective of this study was to determine the effect of PDE-5is on the incidence of major adverse cardiovascular (CV) events (MACE;...

Mar 10th, 2023 - The available literature on morbidity risk of cardiovascular diseases associated with ambient ozone pollution is still limited. This study examined the potential acute effects of exposure to ambient ozone pollution on hospital admissions of cardio...

Aug 4th, 2022 - Cardiovascular disease (CVD), including congestive heart failure (CHF), coronary heart disease (CHD), angina pectoris (AP), heart attack and stroke, is a major public health challenge and among the leading causes of mortality worldwide (1). The CV...

Apr 28th, 2016 - Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force provides annually updated, evidence-based recommendations to guide the diagnosis, assessment, prevention, and treatment of hypertension. This year, we present 4 ne...

Jul 9th, 2009 - Recommendations for advancing the care of Canadians living with refractory angina pectoris: a Canadian Cardiovascular Society position statement.|2009|McGillion M,L'Allier PL,Arthur H,Watt-Watson J,Svorkdal N,|epidemiology,therapy,epidemiology,

Sildenafil, approved two decades ago, is the inhibitor of phosphodiesterase 5 (PDE5). First of all, it was designated for angina pectoris, but soon it showed a wonderful efficacy in erectile dysfunction (ED) and then pulmonary arterial hypertensio...

Mar 6th, 2023 - About 50 patients with clinical evidence of ischemic heart disease and / or a positive functional study and documented stable angina pectoris (Canadian cardiovascular society classification (CCS)1, 2, 3 or 4), or documented silent ischemia in de-n...

Mar 1st, 2023 - Acute coronary syndrome (ACS) is one of the leading causes of coronary artery disease (CAD) death worldwide. Vulnerable plaque rupture is a primary underlying cause of luminal thrombosis responsible for provoking ACS. Therefore, identifying high-r...

Feb 24th, 2023 - The examination and treatment data of 255 patients operated in the Cardiosurgical Department of the Medical Center Hospital of the Presidential Administration of the Republic of Kazakhstan were included in the study. All patients underwent mitral,...

Feb 23rd, 2023 - Design: This study is a single-blinded, randomized clinical trial conducted in the National Cardiovascular Center Harapan Kita, and aims to investigate the effect of the mobile application "HARKIT I-Care" on the morbidity and mortality of post-acu...

Feb 10th, 2023 - To describe antiischemic and antianginal effectiveness of trimetazidine OD 80 mg as well as adherence to the treatment with TMZ 80 mg OD in patients with stable angina pectoris and prior MI in real clinical practice in Russia

Oct 24th, 2022 - Results from an observational study exploring the link between dairy intake and risk of cardiovascular disease events in patients with stable angina pectoris suggest different dairy products may have different health effects. The study, which anal...

Sep 10th, 2022 - Amcenestrant (SAR439859) did not significantly improve progression-free survival (PFS) over physician’s choice of endocrine monotherapy in patients with endocrine-resistant, estrogen receptor (ER)–positive, HER2-negative advanced breast cancer, bu...

Aug 29th, 2022 - The European Commission (EC) has approved asciminib (Scemblix) for the treatment of patients with Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML) in chronic phase who received prior treatment with at least 2 TKIs.1 The appr...

Aug 4th, 2022 - Cardiovascular disease (CVD), including congestive heart failure (CHF), coronary heart disease (CHD), angina pectoris (AP), heart attack and stroke, is a major public health challenge and among the leading causes of mortality worldwide (1). The CV...

May 20th, 2022 - The addition of orteronel (TAK-700) to androgen deprivation therapy (ADT) vs bicalutamide improved progression-free survival (PFS) and prostate-specific antigen (PSA) response in patients with metastatic hormone-sensitive prostate cancer (mHSPC), ...